Clinical Trials
126 trialsNCT05152147 2026-05-19
HERIZON-GEA-01
Jazz Pharmaceuticals
Phase 3 Active not recruiting
NCT05615818 2026-05-19
SAFIR-ABC10
UNICANCER
Phase 3 Recruiting
NCT06467357 2026-05-14
DESTINY-BTC01
AstraZeneca
Phase 3 Recruiting
NCT03017326 2026-05-13
PHITT
University of Birmingham
Phase 3 Active not recruiting
NCT04210115 2026-05-13
KEYNOTE 975
Merck Sharp & Dohme LLC
Phase 3 Active not recruiting
NCT04550260 2026-05-13
KUNLUN
AstraZeneca
Phase 3 Active not recruiting
NCT06764875 2026-05-12
A Phase â ¢ Study of Rilvegostomig in Combination With Fluoropyrimidine and Trastuzumab Deruxtecan as the First-line Treatment for HER2-positive Gastric Cancer
AstraZeneca
Phase 3 Recruiting
NCT06282575 2026-05-11
Efficacy and Safety of Zanidatamab With Standard-of-care Therapy Against Standard-of-care Therapy for Advanced HER2-positive Biliary Tract Cancer
Jazz Pharmaceuticals
Phase 3 Recruiting
NCT00980460 2026-05-04
Risk-Based Therapy in Treating Younger Patients With Newly Diagnosed Liver Cancer
National Cancer Institute (NCI)
Phase 3 Active not recruiting
NCT04478292 2026-05-04
A Multi-institutional Study for Treatment of Children With Newly Diagnosed Hepatoblastoma Using a Modified PHITT Strategy
Shanghai Children's Medical Center
Phase 3 Recruiting
NCT05357846 2026-04-30
PD-1 Inhibitor Combined With Neoadjuvant Chemoradiotherapy Plus Surgery for Locally Advanced ESCC (NEOCRTEC2101)
Sun Yat-sen University
Phase 3 Recruiting
NCT05771480 2026-04-21
TOURMALINE
AstraZeneca
Phase 3 Active not recruiting
NCT04924062 2026-04-15
KEYNOTE-966
Merck Sharp & Dohme LLC
Phase 3 Completed
NCT03957590 2026-04-13
A Study to Investigate Tislelizumab (BGB-A317) Versus Placebo in Combination With Concurrent Chemoradiotherapy in Participants With Localized Esophageal Squamous Cell Carcinoma
BeOne Medicines
Phase 3 Completed
NCT04540211 2026-04-09
SKYSCRAPER-08
Hoffmann-La Roche
Phase 3 Completed
NCT04003636 2026-03-24
KEYNOTE-966
Merck Sharp & Dohme LLC
Phase 3 Completed
NCT07221253 2026-03-17
AB02
AstraZeneca
Phase 3 Recruiting
NCT03221426 2026-03-09
KEYNOTE-585
Merck Sharp & Dohme LLC
Phase 3 Completed
NCT04882241 2026-03-06
KEYNOTE-585
Merck Sharp & Dohme LLC
Phase 3 Completed
NCT06109779 2026-03-04
Rilvegostomig + Chemotherapy as Adjuvant Therapy for Biliary Tract Cancer After Resection (ARTEMIDE-Biliary01)
AstraZeneca
Phase 3 Active not recruiting
NCT03675737 2026-02-27
KEYNOTE-859
Merck Sharp & Dohme LLC
Phase 3 Completed
NCT07229625 2026-01-28
A Phase III Study of SHR-8068 in Combination With Adebrelimab and Platinum-Containing Chemotherapy Versus Durvalumab in Combination With Platinum-Containing Chemotherapy as First-line Treatment for Advanced Biliary Tract Cancer (BTC)
Suzhou Suncadia Biopharmaceuticals Co., Ltd.
Phase 3 Recruiting
NCT06591520 2026-01-21
AK112 Combined With Chemotherapy Versus Durvalumab Combined With Chemotherapy in Advanced Biliary Tract Cancer
Akeso
Phase 3 Active not recruiting
NCT03768414 2026-01-12
Gemcitabine Hydrochloride and Cisplatin With or Without Nab-Paclitaxel in Treating Patients With Newly Diagnosed Advanced Biliary Tract Cancers
SWOG Cancer Research Network
Phase 3 Completed
NCT06676449 2026-01-07
TDLN-sparing RT Plus Immunotherapy and Chemotherapy in Locally Advanced ESCC
Fudan University
Phase 3 Recruiting
NCT03533582 2025-12-22
Cisplatin and Combination Chemotherapy in Treating Children and Young Adults With Hepatoblastoma or Liver Cancer After Surgery
Children's Oncology Group
Phase 3 Active not recruiting
NCT04949256 2025-12-15
MK-7902-014
Merck Sharp & Dohme LLC
Phase 3 Active not recruiting
NCT03615326 2025-12-11
MK-3475-811
Merck Sharp & Dohme LLC
Phase 3 Completed
NCT03656536 2025-08-24
FIGHT-302
Incyte Corporation
Phase 3 Terminated
NCT03783442 2025-07-29
A Study of Tislelizumab (BGB-A317) in Combination With Chemotherapy as First Line Treatment in Participants With Advanced Esophageal Squamous Cell Carcinoma
BeiGene
Phase 3 Completed
NCT07062263 2025-07-14
TAB-2
Tata Memorial Centre
Phase 3 Recruiting
NCT05342194 2025-04-23
Toripalimab Plus Lenvatinib and Gemcitabine-based Chemotherapy in 1L Treatment of Advanced ICC: a Phase III Study
Shanghai Junshi Bioscience Co., Ltd.
Phase 3 Recruiting
NCT02170090 2025-03-30
ACTICCA-1
UniversitÀtsklinikum Hamburg-Eppendorf
Phase 3 Active not recruiting
NCT05919030 2024-11-14
A Study of Chemoradiation in Combination with Tislelizumab As First Line Treatment in Participants with Advanced Esophageal Squamous Cell Carcinoma
Renmin Hospital of Wuhan University
Phase 3 Recruiting
NCT03673072 2024-11-12
GAIN
Krankenhaus Nordwest
Phase 3 Completed
NCT04447352 2024-11-12
PREVENT
Krankenhaus Nordwest
Phase 3 Recruiting
NCT03189719 2024-10-15
KEYNOTE-590
Merck Sharp & Dohme LLC
Phase 3 Completed
NCT01285557 2024-09-19
DIGEST
Taiho Oncology, Inc.
Phase 3 Terminated
NCT06022861 2024-09-19
A Study to Compare the Efficacy and Safety of LY01015 and Opdivo® Combined Respectively With Chemotherapy in Advanced or Metastatic Esophageal Squamous Cell Carcinoma
Shandong Boan Biotechnology Co., Ltd
Phase 3 Recruiting
NCT03773302 2024-05-08
Phase 3 Study of BGJ398 (Oral Infigratinib) in First Line Cholangiocarcinoma With FGFR2 Gene Fusions/Translocations
QED Therapeutics, a BridgeBio company
Phase 3 Terminated
NCT02465736 2024-01-16
Study of Docetaxel or Vinorelbine Plus Cisplatin in Neoadjuvant Chemoradiotherapy for Esophageal Cancer (NEOCRTEC308)
Sun Yat-sen University
Phase 3 Unknown
NCT01004978 2024-01-03
Chemoembolization With or Without Sorafenib Tosylate in Treating Patients With Liver Cancer That Cannot Be Removed by Surgery
National Cancer Institute (NCI)
Phase 3 Completed
NCT03748134 2023-10-24
Sintilimab or Placebo With Chemotherapy in Esophageal Squamous Cell Carcinoma ( ORIENT-15 )
Innovent Biologics (Suzhou) Co. Ltd.
Phase 3 Completed
NCT04163900 2023-05-24
Comparing NUC-1031 Plus Cisplatin to Gemcitabine Plus Cisplatin in Patients With Advanced Biliary Tract Cancer
NuCana plc
Phase 3 Terminated
NCT02494583 2023-04-13
MK-3475-062
Merck Sharp & Dohme LLC
Phase 3 Completed
NCT05766605 2023-03-13
Applicability of PDOX in Patients With Primary Liver Cancer: A Randomized Controlled Trial
Zhujiang Hospital
Phase 3 Unknown
NCT03691090 2022-12-07
Study of SHR-1210 in Combination With Chemotherapy in Advanced Esophageal Cancer
Jiangsu HengRui Medicine Co., Ltd.
Phase 3 Completed
NCT01726452 2022-09-30
NEOadjuvant Trial in Adenocarcinoma of the oEsophagus and oesophagoGastric Junction International Study (Neo-AEGIS)
Cancer Trials Ireland
Phase 3 Completed
NCT00655876 2022-06-14
Paclitaxel, Cisplatin, and Radiation Therapy With or Without Cetuximab in Treating Patients With Locally Advanced Esophageal Cancer
Radiation Therapy Oncology Group
Phase 3 Completed
NCT04807673 2022-06-01
KEYSTONE-002
Tianjin Medical University Cancer Institute and Hospital
Phase 3 Recruiting